All In Biotech

Drug Trial Radar · NCT07000123

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 3,103 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,103

Actual

Start

May 28, 2025

Primary completion

Jan 11, 2027

Study completion Jan 11, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Conditions

  • Cardiovascular Disease

Interventions

  • AZD0780Drug

    Participants will receive daily oral dose of AZD0780

  • PlaceboDrug

    Participants will receive daily oral dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in LDL-C from baseline to 12 weeksTime frame: Baseline - 12 weeks

Locations

404 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Irondale, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Sun City West, Arizona

  • Research Site

    Garden Grove, California

  • Research Site

    Gardena, California

  • Research Site

    Lancaster, California

  • Research Site

    Lincoln, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Torrance, California

  • Research Site

    West Hills, California

  • Research Site

    Hamden, Connecticut

  • Research Site

    Boca Raton, Florida

  • Research Site

    Hallandale, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Inverness, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    New Port Richey, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Seminole, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Peachtree Corners, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Winfield, Illinois

  • Research Site

    Evansville, Indiana

  • Research Site

    Evansville, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Ames, Iowa

  • Research Site

    El Dorado, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Owensboro, Kentucky

  • Research Site

    Hammond, Louisiana

Showing 40 of 404 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.